SANASana Biotechnology, Inc.
Sign up free
Thesis

UP421's 52-week immunosuppression-free graft survival anchors the SC451 bet, but cash runs to mid-2027 and first human data must validate the HIP platform before the runway closes

Updated 7d ago

Sana Biotechnology is a clinical-stage cell therapy company developing transplantable insulin-producing cells for type 1 diabetes, with its lead program not yet approved.

Sana's core bet is that HIP-modified allogeneic islet cells can restore insulin production in type 1 diabetes without immunosuppression, a claim supported by UP421 showing 52-week graft survival and C-peptide production in humans. SC451, the GMP iPSC-derived successor, must replicate that signal in Phase 1 to validate the platform. Cash of $160M supports operations only into mid-2027, leaving minimal buffer if IND filing or early dosing slips.

Status
Challenged
Conviction

Current Thesis Drivers

  • UP421: 52-week graft survival, C-peptide, no immunosuppression
  • SC451 human efficacy unresolved — IND not yet filed
  • $160M cash; mid-2027 runway; $35M quarterly burn
  • SC262 and SC291 both suspended after 2025 trial failures

What could change the thesis?

  • SC451 Phase 1 first data: graft function validates HIP platform, no signal ends pivot
  • SG293 FIH readout: CAR T expansion confirms in vivo platform, miss narrows story further
  • Financing need before mid-2027: dilutive raise manageable, failure to raise is terminal

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

6 programs · 9 catalysts

Stress Test